About
Jan Smeitink is a Dutch mitochondrial-medicine specialist and biotech founder best known for founding Khondrion, a clinical-stage company developing therapies for primary mitochondrial disease. Khondrion's official materials describe him as a long-time leader in mitochondrial medicine, a Professor Emeritus at Radboud University, and a senior figure in the clinical and translational development of sonlicromanol. His public profile is centered on scientific leadership, patient-care expertise, and company building in rare-disease biopharma.
Areas of interest
mitochondrial medicinerare disease therapeuticsbiopharma R&Dprimary mitochondrial diseaseclinical translationpatient advocacy